EGFR and neoplasm: HER2 amplification in CRCs is significantly associated with resistance to anti-EGFR inhibitors and also related to inferior survival outcomes in patients with HER2 positive tumor exposed to chemotherapy with anti-EGFR inhibitors34,35. Therefore, in addition to RAS/RAF molecular tests, HER2 screening is essential for selecting efficacious treatment options for patients with metastatic CRC.